Oslo, Norway, 20 April 2022
Vistin Pharma ASA will release its first quarter 2022 results on Wednesday 27th of April 2022. Vistin Pharma will host a conference call for all shareholders and interested parties on Wednesday 27th of April at 08:30 CET. There will be a Q&A session following the management discussion.
The conference call will be held in English.
The first quarter conference call will be available via web and audio through the following access points:
Telephone conference:
Confirmation Code: 8168697
International dial-In: +44 (0) 2071 928338
Norway, Oslo: +47 21563015
United States, New York: +1 6467413167
Webcast:
https://edge.media-server.com/mmc/p/s56tfz7e
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com
About Vistin Pharma | www.vistin.com
Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.
